Huons Co. Ltd (243070) - Net Assets
Based on the latest financial reports, Huons Co. Ltd (243070) has net assets worth ₩395.25 Billion KRW (≈ $267.86 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩644.23 Billion ≈ $436.59 Million USD) and total liabilities (₩248.98 Billion ≈ $168.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Huons Co. Ltd (243070) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩395.25 Billion |
| % of Total Assets | 61.35% |
| Annual Growth Rate | 17.71% |
| 5-Year Change | 44.88% |
| 10-Year Change | N/A |
| Growth Volatility | 9.83 |
Huons Co. Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Huons Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 243070 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Huons Co. Ltd (2016–2024)
The table below shows the annual net assets of Huons Co. Ltd from 2016 to 2024. For live valuation and market cap data, see Huons Co. Ltd (243070) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩345.97 Billion ≈ $234.46 Million |
+4.71% |
| 2023-12-31 | ₩330.41 Billion ≈ $223.92 Million |
+16.98% |
| 2022-12-31 | ₩282.46 Billion ≈ $191.42 Million |
+6.15% |
| 2021-12-31 | ₩266.09 Billion ≈ $180.33 Million |
+11.43% |
| 2020-12-31 | ₩238.80 Billion ≈ $161.83 Million |
+22.77% |
| 2019-12-31 | ₩194.52 Billion ≈ $131.82 Million |
+19.14% |
| 2018-12-31 | ₩163.27 Billion ≈ $110.64 Million |
+33.07% |
| 2017-12-31 | ₩122.69 Billion ≈ $83.15 Million |
+30.69% |
| 2016-12-31 | ₩93.88 Billion ≈ $63.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Huons Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1627.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩269.46 Billion | 77.88% |
| Common Stock | ₩5.99 Billion | 1.73% |
| Other Components | ₩70.52 Billion | 20.38% |
| Total Equity | ₩345.97 Billion | 100.00% |
Huons Co. Ltd Competitors by Market Cap
The table below lists competitors of Huons Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Context Therapeutics Inc
NASDAQ:CNTX
|
$208.57 Million |
|
EMS Limited
NSE:EMSLIMITED
|
$208.57 Million |
|
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
|
$208.61 Million |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
$208.62 Million |
|
Kejuruteraan Asastera Bhd
KLSE:0193
|
$208.46 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
$208.38 Million |
|
Atrium Therapeutics, Inc. Common Stock
NASDAQ:RNA
|
$208.37 Million |
|
Eastern Media International Corp
TW:2614
|
$208.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Huons Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 325,404,470,470 to 345,970,845,840, a change of 20,566,375,370 (6.3%).
- Net income of 29,453,533,830 contributed positively to equity growth.
- Dividend payments of 7,472,683,350 reduced retained earnings.
- Share repurchases of 5,079,255,050 reduced equity.
- Other factors increased equity by 3,664,779,940.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩29.45 Billion | +8.51% |
| Dividends Paid | ₩7.47 Billion | -2.16% |
| Share Repurchases | ₩5.08 Billion | -1.47% |
| Other Changes | ₩3.66 Billion | +1.06% |
| Total Change | ₩- | 6.32% |
Book Value vs Market Value Analysis
This analysis compares Huons Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.36x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩7853.15 | ₩26400.00 | x |
| 2017-12-31 | ₩10268.06 | ₩26400.00 | x |
| 2018-12-31 | ₩13671.49 | ₩26400.00 | x |
| 2019-12-31 | ₩16292.52 | ₩26400.00 | x |
| 2020-12-31 | ₩20170.84 | ₩26400.00 | x |
| 2021-12-31 | ₩22484.17 | ₩26400.00 | x |
| 2022-12-31 | ₩23877.38 | ₩26400.00 | x |
| 2023-12-31 | ₩27405.84 | ₩26400.00 | x |
| 2024-12-31 | ₩29299.95 | ₩26400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Huons Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.51%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.99%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 1.75x
- Recent ROE (8.51%) is below the historical average (17.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 16.33% | 9.07% | 0.94x | 1.91x | ₩5.95 Billion |
| 2017 | 28.58% | 12.31% | 1.32x | 1.76x | ₩22.80 Billion |
| 2018 | 27.70% | 13.77% | 1.31x | 1.54x | ₩28.91 Billion |
| 2019 | 19.64% | 10.47% | 1.22x | 1.54x | ₩18.76 Billion |
| 2020 | 23.28% | 13.67% | 0.98x | 1.74x | ₩31.70 Billion |
| 2021 | 11.56% | 7.04% | 1.00x | 1.64x | ₩4.14 Billion |
| 2022 | 7.95% | 4.56% | 1.04x | 1.67x | ₩-5.80 Billion |
| 2023 | 15.51% | 9.14% | 1.03x | 1.65x | ₩17.93 Billion |
| 2024 | 8.51% | 4.99% | 0.97x | 1.75x | ₩-5.14 Billion |
Industry Comparison
This section compares Huons Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Huons Co. Ltd (243070) | ₩395.25 Billion | 16.33% | 0.63x | $208.46 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Huons Co. Ltd
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other ch… Read more